View Future GrowthImmix Biopharma 過去の業績過去 基準チェック /06Immix Biopharmaの収益は年平均-22.3%で減少しているが、Biotechs業界はgrowingで30%年平均の収益となった。主要情報-22.29%収益成長率20.83%EPS成長率Biotechs 業界の成長17.04%収益成長率n/a株主資本利益率-31.39%ネット・マージンn/a前回の決算情報31 Dec 2025最近の業績更新更新なしすべての更新を表示Recent updatesImmix Biopharma, Inc., Annual General Meeting, May 22, 2026Apr 07Immix Biopharma Inc Announces Enrollment Completion Of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2 And Upcoming MilestonesMar 30New minor risk - Profitability Mar 29Forecast breakeven date pushed back to 2028 Mar 27New minor risk - Profitability Mar 09Forecast breakeven date pushed back to 2028 Feb 09New major risk - Shareholder dilution Dec 21Immix Biopharma, Inc. Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-In-Class Therapy for Relapsed/Refractory AL AmyloidosisDec 09+ 1 more updateImmix Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $99.995092 million.Dec 08Immix Biopharma, Inc. Appoints Michael Grabow as Chief Commercial OfficerNov 13New major risk - Financial position Nov 09Immix Biopharma, Inc. Announces 50% Enrollment Milestone Surpassed in Its Ongoing Relapsed/Refractory AL Amyloidosis Clinical Trial, NEXICART-2Sep 20New minor risk - Shareholder dilution Sep 10Immix Biopharma, Inc. Appoints Nancy Chang, Ph.D. as A Member of the Board, Effective September 8, 2025Sep 09We Think Immix Biopharma (NASDAQ:IMMX) Needs To Drive Business Growth CarefullyAug 13New major risk - Financial position Aug 11Immix Biopharma, Inc. Announces Other Serious Diseases StrategyAug 07Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication ExpansionJul 11Immix Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $13.45 million.Jun 04New minor risk - Share price stability May 23Immix Biopharma Further Expands U.S. Clinical Sites for Relapsed/Refractory AL Amyloidosis Trial Nexicart-2May 23+ 1 more updateImmix Biopharma, Inc., Annual General Meeting, Jun 20, 2025May 01New major risk - Financial position Mar 25Consensus revenue estimates increase by 100% Mar 16Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?Mar 08Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL AmyloidosisFeb 11New major risk - Shareholder dilution Jan 16Immix Biopharma, Inc. Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-TJan 08New major risk - Revenue and earnings growth Jan 06Independent Director recently bought US$104k worth of stock Dec 29Immix Biopharma Announces Positive U.S. Clinical Data from First Four Patients in Nexicart-2 U.S. Trial of Sterically-Optimized Car-T Nxc-201 in Relapsed/Refractory Light Chain (Al) AmyloidosisDec 19Immix Biopharma, Inc. Announces Journal of Clinical Oncology Publishes NEXICART-2 Clinical Results in Relapsed/Refractory AL AmyloidosisDec 17Immix Biopharma, Inc. Announces New Nxc-201 Nexicart-1 Clinical Data in Relapsed/Refractory Al Amyloidosis Patients At Ash 2024Dec 12Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Deliver On Growth Plans?Nov 11Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2Oct 03Immix Biopharma Announces Raymond Comenzo Joins Scientific Advisory Board of Nexcella Scientific AdvisorySep 19Immix Biopharma, Inc. Announces the Addition of Three Additional Clinical Trial Sites for Its U.S. Relapsed/Refractory Al Amyloidosis Clinical Trial NEXICART-2Aug 29Independent Director recently bought US$52k worth of stock Aug 28Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?Aug 12Immix Biopharma, Inc. Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201Jul 09Insufficient new directors Jul 01New major risk - Revenue and earnings growth Jun 27Immix Biopharma, Inc. Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Latebreaking Oral PresentationMay 11Immix Biopharma, Inc., Annual General Meeting, Jun 11, 2024May 01Immix Biopharma, Inc. Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 Al Amyloidosis Clinical TrialMar 20New major risk - Shareholder dilution Feb 07Immix Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $14.999999 million.Feb 06+ 1 more updateNew minor risk - Market cap size Jan 24Director recently bought US$267k worth of stock Dec 14Immix Biopharma, Inc. Announces New Clinical Data from Its Phase 1b/2a NEXICART-1Dec 12Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?Nov 28Immix Biopharma, Inc. to Host KOL Event to Discuss Its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL AmyloidosisNov 23New major risk - Financial position Nov 15Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis PatientsNov 07Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing SiteOct 17Immix Biopharma Inc. Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple MyelomaOct 05+ 1 more updateDirector recently bought US$200k worth of stock Sep 20Immix Biopharma, Inc Announces U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple MyelomaAug 24Immix Biopharma, Inc. Appoints Yekaterina Chudnovsky as Member of the BoardAug 23+ 2 more updatesImmix Biopharma, Inc. Reports 2Nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1B/2A Imx-110 Imx-110 Clinical TrialJul 18Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?Jul 12We're Not Very Worried About Immix Biopharma's (NASDAQ:IMMX) Cash Burn RateMar 29Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced CancerFeb 08Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical TrialJan 14Immix Biopharma, Inc. Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical TrialDec 21Immix Biopharma, Inc. Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX 110 in Advanced Solid TumorsDec 20Immix Biopharma Announces Patient Dosing in Ongoing Phase 1B/2A Imx-110 Monotherapy Clinical TrialDec 15Immix Biopharma, Inc. Releases and Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient DosingDec 13High number of new directors Nov 16Immix Biopharma, Inc. Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical TrialNov 12Immixbio Approves 4 Additional Clinical Trial Sites for Imx-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead SiteOct 19Immix Biopharma (NASDAQ:IMMX) Is In A Good Position To Deliver On Growth PlansSep 13Immix Biopharma, Inc. Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical TrialsSep 08Immix Biopharma, Inc. Announces Positive Interim Study Data Showing That After One Cycle of Treatment, Immixbio's Lead Candidate IMX-110 Produces 75% Survival Vs. 0% Survival for TrabectedinMay 21We're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash WiselyMay 21High number of new and inexperienced directors Apr 27Immix Biopharma, Inc., Annual General Meeting, Jun 08, 2022Apr 26Immix Biopharma, Inc. Initiates Good Manufacturing Practice Manufacturing of IMX-120Feb 24Immix Biopharma, Inc. Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial DataFeb 01ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment CyclesJan 20Immix Biopharma, Inc IMX-110 Produces 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice StudyJan 13U.S. Food and Drug Administration Approves Immix Biopharma, Inc. Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in ChildrenJan 05High number of new and inexperienced directors Dec 31Immix Biopharma, Inc. has completed an IPO in the amount of $21 million.Dec 17収支内訳Immix Biopharma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqCM:IMMX 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 250-29141630 Sep 250-24121230 Jun 250-23121231 Mar 250-21121031 Dec 240-22111130 Sep 240-22101330 Jun 240-19101131 Mar 240-1891131 Dec 230-157930 Sep 230-147830 Jun 230-115631 Mar 230-95531 Dec 220-84430 Sep 220-273230 Jun 220-263131 Mar 220-252131 Dec 210-241030 Sep 210-21030 Jun 210-20031 Mar 210-20031 Dec 200-100質の高い収益: IMMXは現在利益が出ていません。利益率の向上: IMMXは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: IMMXは利益が出ておらず、過去 5 年間で損失は年間22.3%の割合で増加しています。成長の加速: IMMXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: IMMXは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 40.2% ) と比較することは困難です。株主資本利益率高いROE: IMMXは現在利益が出ていないため、自己資本利益率 ( -31.39% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/01 08:59終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Immix Biopharma, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Reni BenjaminCitizens JMP Securities, LLCJyoti PrakashEdison Investment ResearchRobert BurnsH.C. Wainwright & Co.2 その他のアナリストを表示
Immix Biopharma Inc Announces Enrollment Completion Of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2 And Upcoming MilestonesMar 30
Immix Biopharma, Inc. Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-In-Class Therapy for Relapsed/Refractory AL AmyloidosisDec 09+ 1 more update
Immix Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $99.995092 million.Dec 08
Immix Biopharma, Inc. Announces 50% Enrollment Milestone Surpassed in Its Ongoing Relapsed/Refractory AL Amyloidosis Clinical Trial, NEXICART-2Sep 20
Immix Biopharma, Inc. Appoints Nancy Chang, Ph.D. as A Member of the Board, Effective September 8, 2025Sep 09
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication ExpansionJul 11
Immix Biopharma Further Expands U.S. Clinical Sites for Relapsed/Refractory AL Amyloidosis Trial Nexicart-2May 23+ 1 more update
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL AmyloidosisFeb 11
Immix Biopharma Announces Positive U.S. Clinical Data from First Four Patients in Nexicart-2 U.S. Trial of Sterically-Optimized Car-T Nxc-201 in Relapsed/Refractory Light Chain (Al) AmyloidosisDec 19
Immix Biopharma, Inc. Announces Journal of Clinical Oncology Publishes NEXICART-2 Clinical Results in Relapsed/Refractory AL AmyloidosisDec 17
Immix Biopharma, Inc. Announces New Nxc-201 Nexicart-1 Clinical Data in Relapsed/Refractory Al Amyloidosis Patients At Ash 2024Dec 12
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2Oct 03
Immix Biopharma Announces Raymond Comenzo Joins Scientific Advisory Board of Nexcella Scientific AdvisorySep 19
Immix Biopharma, Inc. Announces the Addition of Three Additional Clinical Trial Sites for Its U.S. Relapsed/Refractory Al Amyloidosis Clinical Trial NEXICART-2Aug 29
Immix Biopharma, Inc. Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Latebreaking Oral PresentationMay 11
Immix Biopharma, Inc. Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 Al Amyloidosis Clinical TrialMar 20
Immix Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $14.999999 million.Feb 06+ 1 more update
Immix Biopharma, Inc. to Host KOL Event to Discuss Its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL AmyloidosisNov 23
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis PatientsNov 07
Immix Biopharma Inc. Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple MyelomaOct 05+ 1 more update
Immix Biopharma, Inc Announces U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple MyelomaAug 24
Immix Biopharma, Inc. Reports 2Nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1B/2A Imx-110 Imx-110 Clinical TrialJul 18
Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced CancerFeb 08
Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical TrialJan 14
Immix Biopharma, Inc. Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical TrialDec 21
Immix Biopharma, Inc. Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX 110 in Advanced Solid TumorsDec 20
Immix Biopharma Announces Patient Dosing in Ongoing Phase 1B/2A Imx-110 Monotherapy Clinical TrialDec 15
Immix Biopharma, Inc. Releases and Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient DosingDec 13
Immix Biopharma, Inc. Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical TrialNov 12
Immixbio Approves 4 Additional Clinical Trial Sites for Imx-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead SiteOct 19
Immix Biopharma, Inc. Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical TrialsSep 08
Immix Biopharma, Inc. Announces Positive Interim Study Data Showing That After One Cycle of Treatment, Immixbio's Lead Candidate IMX-110 Produces 75% Survival Vs. 0% Survival for TrabectedinMay 21
Immix Biopharma, Inc. Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial DataFeb 01
ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment CyclesJan 20
Immix Biopharma, Inc IMX-110 Produces 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice StudyJan 13
U.S. Food and Drug Administration Approves Immix Biopharma, Inc. Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in ChildrenJan 05
